Botox injection improve outcomes for neurogenic bladder in children with spina bifida

A recent study published in the Journal of Pediatric Urology finds a significant surge in the use of intra-detrusor botulinum toxin (Botox) injections as a minimally invasive alternative for treating neurogenic bladder in children with spina bifida.

The recent data analysis conducted at free-standing children’s hospitals revealed a significant increase in the utilization of Botox injections as an alternative approach to augmentation cystoplasty in managing refractory neurogenic bladder among pediatric patients with spina bifida. This trend marks a departure from conventional surgical interventions by signaling a progressive shift in treatment paradigms.

The study was conducted using the Pediatric Health Information System database from 2016 to 2019 and examined the treatment patterns among spina bifida patients who are undergoing either intra-detrusor Botox injection or augmentation cystoplasty. With a sample size comprising 1,924 Botox injections and 842 cystoplasties, the outcomes highlight the evolving preferences in pediatric urology.

The study showed substantial increase in the frequency of intra-detrusor Botox injections over the study period that suggests a growing acceptance and adoption of this minimally invasive technique. While there was a slight decline in augmentation cystoplasty rates outside the summer months, the decrease did not reach statistical significance.